Free Trial
NASDAQ:SAVA

Cassava Sciences Q4 2024 Earnings Report

Cassava Sciences logo
$1.63 +0.01 (+0.62%)
As of 10:44 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cassava Sciences EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.68
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Cassava Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cassava Sciences Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 3, 2025
Conference Call Time
7:30AM ET

Upcoming Earnings

Cassava Sciences' Q1 2025 earnings is scheduled for Friday, May 9, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Cassava Sciences Earnings Headlines

Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new blockchain development…
Cassava Sciences chief medical officer James Kupiec to retire
See More Cassava Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cassava Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cassava Sciences and other key companies, straight to your email.

About Cassava Sciences

Cassava Sciences (NASDAQ:SAVA), a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

View Cassava Sciences Profile

More Earnings Resources from MarketBeat